December 12, 2016—House and Senate committee leaders want the Centers for Medicare & Medicaid Services to answer questions about its handling of the anaphylaxis rescue drug EpiPen by Dec. 20, including whether EpiPen’s misclassification as a generic drug for Medicaid rebate purposes caused hospitals and other healthcare providers in the 340B drug discount program to be overcharged. Meanwhile, a federal healthcare watchdog agency has launched three new investigations stemming from the EpiPen drug pricing scandal.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)